Teladoc Health (TDOC) is back in focus after two key developments: a new partnership that puts its virtual care services on Walmart’s Better Care Services platform and an earnings update that drew a sharp stock reaction.

The recent Walmart partnership and earnings update come on top of a sharp 44.68% 90 day share price return and 27.90% 30 day share price return. However, the 3 year total shareholder return is still down 68.91%, so recent momentum contrasts with a much weaker long term record.

If the rebound in virtual care has your attention, it can be useful to see what else is moving in this space and compare Teladoc with other 37 healthcare AI stocks.

With Teladoc trading at US$7.61 and an intrinsic value estimate pointing to a 44% discount, yet sitting slightly above one analyst target, you have to ask: is this a genuine entry point, or is the market already baking in future growth?

Most Popular Narrative: 7% Overvalued

With Teladoc Health closing at $7.61 against a most followed fair value estimate of about $7.12, the core narrative sees only modest upside from here, built on specific assumptions about growth, margins and discount rates.

Teladoc's continued investment in product innovation including enhanced cardiometabolic programs and integrated mental health offerings positions the company to capture growing demand for digital management of chronic diseases and leverage the increasing need for cost effective care, supporting long term revenue and enrollment growth.

Curious what sits behind that measured upside view? The narrative leans heavily on how quickly margins could shift, how slowly revenue is expected to build, and the earnings multiple that would need to stick to support that fair value.

Result: Fair Value of $7.12 (OVERVALUED)

However, that fair value story can quickly break if BetterHelp’s shift to insurance compresses margins further, or if chronic care competition weighs on enrollment and pricing.

Another Angle: Multiples Tell a Different Story

While the narrative based valuation points to Teladoc Health trading around 7% above its fair value, the simple P/S picture looks very different. At about 0.5x sales versus 2.2x for the US Healthcare Services industry and a 2x fair ratio, the stock screens as much cheaper on revenue. Is this a value trap, or is the market overcompensating for the risks?

Next Steps

Given the mixed signals in this story, it makes sense to look at the numbers yourself and weigh both the risks and rewards. To pressure test your own view before the market moves again, start by checking the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Teladoc has sharpened your focus, do not stop here. There are plenty of other stocks that could suit your goals and risk comfort.

• Target potential mispricings by scanning 46 high quality undervalued stocks that pair solid fundamentals with a discount to their estimated worth.
• Strengthen your income stream by reviewing 10 dividend fortresses offering higher yields backed by resilient payouts.
• Sleep easier at night by checking 62 resilient stocks with low risk scores that combine sturdier balance sheets with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.